Orion Genomics Licenses Methylation Technology to Qiagen | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Orion Genomics today said that it has licensed to Qiagen non-exclusive rights to its MethylScreen technology for epigenetics research.

Qiagen will use the MethylScreen technology in its EpiTect Methyl qPCR Array System reagent kits, which are used by researchers to analyze the DNA methylation status of genes with quantitative PCR.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.